



UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche

CURRICULUM VITAE CRISTINA PELLEGRINI



PERSONAL INFORMATION	Cristina Pellegrini Department of Biotechnological and Applied Clinical Sciences via Vetoio, Coppito 2 L'Aquila, 67100, Italia Cristina.pellegrini@univaq.it
CURRENT POSITION	<b>Assistant Professor (Tenure-track position) in Dermatology (MED-35)</b> Department of Biotechnological and Applied Clinical Sciences. University of L'Aquila, L'Aquila Italy
EDUCATION OTHER QUALIFICATIONS	<p>1999-2004. M.S. in Biological Sciences, Department of Biomedical Sciences and Technologies, University of L'Aquila, Italy.</p> <p>2004-2008. PhD in Experimental Medicine. Department of Biomedical Sciences and Technologies, University of L'Aquila, Italy.</p> <p>2008-2012. Specialist in Clinical Biochemistry and Clinical Molecular Biology. Department of Biomedical Sciences and Technologies, University of L'Aquila. Italy.</p> <p>2021-to date. II level Master in Epidemiology and Biostatistics for the Clinical Research. University of Milano Bicocca, Italy.</p> <p><b>Other Education/Training</b></p> <p>2020. Course "Percorso diagnostico nei pazienti con mutazioni BRAF nel NSCLC e nel Melanoma". 20 Ottobre. Novartis. Web Live.</p> <p>2020. Course "Post-Chicago Melanoma/Skin Cancer Meeting". European Academy Dermatology Venereology. Web Live</p> <p>2020. Minifaculty "MELANOMA –FORWARD AND BEYOND 2.0" Novartis. Web Live.</p> <p>2020. "BIG DATA nell'innovazione terapeutica in Oncologia". NIBIT, Network Italiano per la bioterapia dei Tumori. Siena, Italia.</p> <p>2019. Minifaculty: "Forward and Beyond - Ridefiniamo il trattamento del melanoma nel paziente BRAF+ ". Novartis. Chieti, Italia.</p> <p>2018. "Data analysis for Microbioma" SIGU, Società Italiana di Genetica Medica. Roma, Italia.</p> <p>2018. "MoRE - Melanoma Reality Experience ". Novartis. Roma, Italia.</p> <p>2018. 155th Course of the International School of Medical Science "The new Era of Medicine: from diagnosis to clinical management".. SIBIOC, Società Italiana di Biochimica Clinica e biologia Molecolare Clinica. Erice, Italia.</p> <p>2018. "Analysis and interpretation of clinical genomics data". SIGU, Società Italiana di Genetica Medica, Roma, Italia.</p> <p>2016. Course "Approccio Multidisciplinare al paziente con BCC avanzato e</p>



	<p>metastatico". ASL.1 Avezzano-Sulmona-L'Aquila. L'Aquila, Italia.</p> <p>2016. "NGS e studio dell'espressione genica: dal campione al risultato" Qiagen Italia. L'Aquila.</p> <p>2017. "Trasferimento Tecnologico in Medicina". SIBIOC, Società Italiana di Biochimica Clinica e biologia Molecolare Clinica. Firenze, Italia.</p> <p>2015. "Bioinformatics approach for the expression analysis". AICC, Associazione Italiana colture Cellulari. Bologna, Italy.</p> <p>2014. "Bioinformatics for Molecular Biologist training course". ThermoFisher. Milano, Italia.</p> <p>2013. "HPLC and GC chromatography for analysis of pharmaceutical, clinical and biological samples". Regione Abruzzo, L' Aquila.</p> <p>2013. "Capillary electrophoresis sequencing Training course: 3500" ThermoFisher. Milano, Italia.</p> <p>2011. "Basic Real Time PCR training". ThermoFisher. Milano, Italia.</p> <p>2008. "Enzyme and protein chemistry - Enzyme kinetics– Protein folding and stability". Università di Firenze, Firenze.</p>

<p>ACADEMIC APPOINTMENTS</p>	<p><b>Appointments in Italian Institutes</b></p> <p>2011-2013. Post-doc Fellowship. Title of the project: "The IL-23/TH17 pathway in the pathogenesis of non-melanoma skin cancers and in the therapeutic response to medical treatments (imiquimod and photodynamic therapy)". Department of Scienze Cliniche Applicate e Biotecnologiche. University of L'Aquila. STATUS: Research Associate</p> <p>2013-2017. Post-doc Fellowship. Title of the project: "Molecular analysis of high-, intermediate- and low-penetrance cutaneous melanoma susceptibility genes in familial melanoma and multiple melanoma patients". Department of Scienze Cliniche Applicate e Biotecnologiche. University of L'Aquila. STATUS: Research Associate</p> <p>2017-2020. Research Fellowship. Title of the project: "Next-generation sequencing technologies for the identification of molecular subtypes of cutaneous melanoma and potential clinical relevance". Department of Scienze Cliniche Applicate e Biotecnologiche. University of L'Aquila. STATUS: Senior Research Associate</p>
------------------------------	---



	<p>2020. Research Fellowship. Title of the project: "Data analysis for the project the use of 0.5% 5-FU in combination with 10% salicylic acid vs. cryotherapy for the treatment of actinic keratosis of the upper extremities". Department of Scienze Cliniche Applicate e Biotecnologiche. University of L'Aquila. STATUS: Senior Research Associate</p> <p><b>Appointments in International Research Institutes</b></p> <p>2007;2010. Visiting Research Fellows. Laboratory of Biological macromolecules. Center for Protein Engineering (CIP) - Faculty of Science. University of Liège, Belgium. Title of the project: "Title of the project: "Molecular and biochemical study of metallo-beta-lactamases".</p> <p>2014. National Cancer Institute, NIH, Bethesda, USA. Visiting Research Fellowship. Advanced Technologies Center, Genetic Epidemiology Branch. Title of the project: "Next-generation sequencing approach to discover molecular subtypes of cutaneous melanoma".</p>
<p>CLINIC APPOINTMENTS</p>	<p>2015-to date. Participation as Responsible of biological samples in the following Clinical Trials at the UOSD Dermatologia Generale ed Oncologica DU, Ospedale San Salvatore, L'Aquila:</p> <ul style="list-style-type: none"> <li>• "A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of Dupilumab in adult patients with moderate- to-severe atopic dermatitis". 2015. Protocol n. R668-AD-1225//Study OLE. Sponsor: Regeneron Pharmaceuticals.</li> <li>• "A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with moderate- to-severe atopic dermatitis. Protocol n. R668-AD-1416 // Study Solo 2 Sponsor: Regeneron Pharmaceuticals.</li> <li>• "PD-1 monoclonal antibody in patients with advanced and metastatic basal cell carcinoma, resistant to anti-hedgehog therapy". Phase II, Protocol number: REGN2810 (Regeneron Pharmaceuticals).</li> <li>• Multicenter Randomized Assessor Blinded Vehicle and Active (topical corticosteroid and calcineurin inhibitor) controlled, parallel group study of the efficacy, safety and local tolerability of crisaborole ointment 2% in pediatric and adult subject with mild to moderate atopic dermatitis". Fase III, Protocol number: PFIZER C3291037_A PHASE</li> </ul>



	<p>3B/4, (Pfizer).</p> <p>2018-to date Responsible of the “Melanoma molecular diagnostic” group within the Molecular Diagnostics and Advanced Therapy Research Center (DMTA), at the ASLn.1 Avezzano-L'Aquila-Sulmona Hospitals and University of L'Aquila L'Aquila, Italy.</p>
<b>TEACHING EXPERIENCE</b>	<p>2010-2011. University of L'Aquila. Bachelor's level degree course in Biotechnologies. Course of “Molecular biology and Clinical biochemistry” for Bachelor students.</p> <p>2017-2020. University of L'Aquila I level Specializing-Master in " Molecular Diagnostics of Genetic, Tumorous and Infective Diseases” Course “NGS: sistema Ion-Torrent”.</p> <p>2021-to date. University of L'Aquila. Course “Oncological Dermatology” at:</p> <ul style="list-style-type: none"> <li>• Master's level degree in Medicine and Surgery.</li> <li>• Schools of Specialization in Clinical Pathology and Biochemistry.</li> <li>• First level Specializing-Master in " Molecular Diagnostics of Genetic, Tumorous and Infective Diseases”.</li> </ul> <p>2022-2023. University of L'Aquila. Master's level degree in Biotechnologies. Course “Molecular biomarkers for precision medicine in skin cancers”.</p>
<b>RESEARCH ACTIVITIES</b>	<p><b>Research Interest</b></p> <p>2004-2010. The research activity was focused on the molecular genetics and biochemistry of antibiotic resistance.</p> <ul style="list-style-type: none"> <li>- Molecular characterization of antibiotics resistance genes</li> <li>- Genetic epidemiology of antibiotics resistance genes</li> <li>- Study of mutant variant produced by in vitro mutagenesis involved in resistance mechanisms</li> <li>- Study of the genetic structure and epidemiology of mobile genetic elements, such as integrons and transposons, involved in the spread of beta-lactam antibiotic resistance genes in gram-negative microorganisms.</li> <li>- Biochemical characterization of resistance genes</li> </ul> <p>2011-to date. The research activity is mainly focused on the study of molecular mechanisms underlying skin disease.</p> <p><i>Melanoma</i></p> <ul style="list-style-type: none"> <li>- Genetic mechanisms of melanoma susceptibility in familial, multiple and pediatric melanoma patients (analysis of sequences in predisposition genes, splicing variants)</li> </ul>



	<ul style="list-style-type: none"> <li>- Analysis of somatic genetic alterations causing the melanoma progression from primary to metastatic lesions.</li> <li>- Role of somatic splice variants of the TRKA gene associated with gene amplification in melanoma.</li> <li>- Inter-tumoral heterogeneity of mutational profiles in patients with multiple melanomas.</li> <li>- GWAS analysis (in collaboration with Genetic Epidemiology Branch, National Cancer Institute, USA).</li> <li>- Exome sequencing analysis in families with melanoma predisposition (in collaboration with the Genetic Epidemiology Branch National Cancer Institute).</li> <li>- Role of methylation (whole genome methylation) in the anti-tumor immune response (in collaboration with the Genetic Epidemiology Branch, National Cancer Institute, USA).</li> <li>- Analysis of miRNA, and miRNoma in melanoma.</li> <li>- Analysis of new molecular prognostic biomarkers by liquid biopsy.</li> </ul> <p><i>Non-melanoma skin cancers</i></p> <ul style="list-style-type: none"> <li>- Epidemiology of Non-melanoma skin cancers</li> <li>- Analysis of molecular alteration in the pathogenesis of non-melanoma skin cancers</li> <li>- Expression of immune and inflammatory mediators during non-melanoma skin cancers pathogenesis and in response to medical treatments.</li> <li>- Evaluation of efficacy, tolerability of therapeutic treatments of non-melanoma skin cancers</li> </ul> <p><i>Atopic dermatitis</i></p> <ul style="list-style-type: none"> <li>- Evaluation of efficacy, tolerability of therapeutic treatments of atopic dermatitis</li> <li>- In vitro biochemical study on endocannabinoid receptor in atopic dermatitis</li> </ul> <p><i>Psoriasis</i></p> <ul style="list-style-type: none"> <li>- Role of plasmacytoid dendritic cells and monocytes in psoriasis</li> </ul> <p><b>Funds as PI/co-PI</b></p> <p>2015. Grant for Scientific independence research “Premialità Bando SIR”. Funded by University of L’Aquila Project title: “Next-generation sequencing technologies for the identification of molecular subtypes of cutaneous melanoma and potential clinical relevance”.</p> <p>2021. DISCAB Grant-2022. Funded by DISCAB, University of L’Aquila.</p>
--	---



	<p>Project title: “Effect of agonists and antagonists of the endocannabinoid system on the cellular model of atopic dermatitis”.</p> <p>2022. Investigator-Initiated Study (IIS). Funded by Janseen Group Project title: “Characterization of the inflammatory microenvironment of cutaneous squamous cell carcinoma and role of the IL-23/Th17 pathway during tumor progression”.</p> <p>2022. DISCAB Grant-2022. Funded by DISCAB, University of L’Aquila. Project title: “Effect of agonists and antagonists of the Endocannabinoid system on the cellular model of atopic dermatitis: Un update”.</p> <p>2022. Progetti di Ateneo-2022. Funded by University of L’Aquila. Project title: “Unravelling the biologic complexity of atypical melanocytic tumors to define a diagnostic algorithm for differential diagnosis, clinical decision-making and management of patients.</p> <p>2023. DISCAB Grant-2022. Funded by DISCAB, University of L’Aquila. Project title: “Role of CB2 and PPAR<math>\alpha</math> endocannabinoid receptors in the pathogenesis of atopic dermatitis”.</p> <p><b>Congress activities</b></p> <p>2006-to date. Author of posters at National and International Meetings for over 50 events</p> <p>2013 to date. Invited Speaker and/or Chairman at National and International Meetings for over 30 events.</p> <p><b>Honor and Awards</b></p> <p>2007. Award for “Research Activity and high Education” funded by European Social Fund for Regional development POR C3/IC4E, POR-2007 type A.</p> <p>2018. “Future Leaders in Dermatology” award, funded by European Society for Dermatological Research (ESDR).</p> <p>2018. National Scientific Habilitation for Associate Professor 05/E3 CLINICAL BIOCHEMISTRY AND MOLECULAR BIOLOGY</p>
--	--



	<p>2019. Lilly Awards Grant for the Abstract presented at 49<sup>th</sup> Annual ESDR Meeting (Bordeaux, France 18-20 September 2019) founded by the European Society for Dermatological Research (ESDR).</p> <p>2019. National Scientific Habilitation for Associate Professor 06/D4- MED35 DERMATOLOGY</p>
<p><b>RESPONSIBILITY IN ACADEMIC ACTIVITIES</b></p>	<p>2021-to date. Member of Clinical Studies Committee at DISCAB department, University of L'Aquila.</p> <p>2023-to date. Member of Internationalization Committee at DISCAB department, University of L'Aquila.</p>
<p><b>EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP</b></p>	<p><b>EDITORIAL ACTIVITIES</b></p> <p>2019-to date. Editorial member: "Frontiers in Molecular Biosciences" (Section: Molecular Diagnostics). ISSN: 2296-889X. Impact Factor: 6.11</p> <p>2019-2022. Topic Editor for the special Issue: "Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction" Journal: "Frontiers in Molecular Biosciences" Impact Factor: 6.11</p> <p>2020–2022. Guest Editor for the special Issue "New Tools and Molecular Advances in Hyperproliferative Skin Disorders!" Journal: "Frontiers in Medicine" Impact Factor: 5.06</p> <p>2023. Topic Editor for the special Issue "Up-date on Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction". Journal: "Frontiers in Molecular Biosciences" Impact Factor: 6.11</p> <p>Reviewer for the following international peer-reviewed journal (indexed by Scopus/WOS/PubMed):</p> <ul style="list-style-type: none"> <li>- Scientific Report</li> <li>- Journal of the European Academy of Dermatology and Venereology</li> <li>- Plos One</li> <li>- Plos Genetics</li> </ul>



	<ul style="list-style-type: none"> <li>- Melanoma Research</li> <li>- Clinical and Experimental Dermatology</li> <li>- Experimental Dermatology</li> <li>- Oncotarget</li> <li>- Journal of Dermatological Science</li> <li>- Technology in Cancer Research &amp; Treatment</li> <li>- Frontiers in Molecular Biosciences</li> <li>- Frontiers in Medicine</li> </ul> <p><b>MEMEBERSHIP</b></p> <p><u>Appointments</u></p> <p>2020-to date. Member of the Scientific Committee SIDEMAST SIDEMAST, Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse.</p> <p><u>Ordinary member</u></p> <p>2015–to date. European Society for Dermatological Research (ESDR) 2016–to date. Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse (SIDEMAST) 2017–to date. Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC) 2017–to date. Società Italiana di Colture Cellulari (AICC) 2017–to date. MelaNostrum Consortium (Conorzio Internazionale per la ricerca sul Melanoma nei paesi del Mediterraneo) 2018–to date. Società Italiana Genetica Umana (SIGU) 2018–to date. IMI (Italian Melanoma Intergroup)</p>
<p>SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS</p>	<p>Author of 65 original articles (indexed by Scopus, WOS), 4 book chapters and 15 published Abstracts.</p> <p><b>ORCID:</b> <a href="https://orcid.org/0000-0003-2168-8097">https://orcid.org/0000-0003-2168-8097</a></p> <p><b>Scopus Author ID:</b> 12808763700</p> <p>H Index=17 Nr. Citations= 1186</p>
<p>SELECTED PUBLICATIONS</p>	<p>5 selected publications in the last 5 years:</p> <p><b>MC1R variants in childhood and adolescent melanoma: A pooled- analysis from a large worldwide multicenter cohort of patients.</b> <u>Pellegrini C</u>, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, et al. Lancet Child Adolesc Health. 2019; 3(5):332-342.</p>





UNIVERSITÀ  
DEGLI STUDI  
DELL'AQUILA



DISCAB  
Dipartimento di Scienze  
Cliniche Applicate  
e Biotecnologiche



	<p><b>Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.</b> Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, <u>Pellegrini C</u>, et al. Nat Genet. 2020; 52(5):494-504.</p> <p><b>Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.</b> <u>Pellegrini C</u>, Cardelli L, Padova M, Nardo LD, Ciciarelli V, Rocco T, Cipolloni G, Clementi M, Cortellini A, Ventura A, Leocata P, Fargnoli MC.. Acta Derm Venereol. 2020; 100(1):adv00040.</p> <p><b>Molecular alterations in basal cell carcinoma subtypes.</b> Di Nardo L, <u>Pellegrini C*</u>, Di Stefani A, Ricci F, Fossati B, Del Regno L, Carbone C, Piro G, Corbo V, Delfino P, De Summa S al. Sci Rep. 2021;11(1):13206. *co-first author</p> <p><b>Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients</b> <u>Pellegrini C</u>, Raimondi S, Di Nardo L, Ghorzo P, Menin C, Manganoni MA, Palmieri G, Guida G, Quaglino P, et al. J Eur Acad Dermatol Venereol. 2022; 36(2):213-221.</p>
--	---

PLACE AND DATE

L'AQUILA, 29/03/2023